Biocon Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon Limited reported Q3 FY26 consolidated revenue from operations of Rs 41,730 million, up 9.2% YoY from Rs 38,214 million, but swung to a consolidated net loss of Rs 518 million (vs profit of Rs 811 million YoY) on exceptional items of Rs 2,934 million. Standalone, the company posted a net loss of Rs 764 million versus a profit of Rs 5,840 million a year ago, with EPS at Rs (0.57), hurt by Rs 1,963 million in exceptional charges including BBL integration advisory costs and Labour Code-related gratuity provisions. For the 9-month period, consolidated revenue grew 14.4% to Rs 1,24,104 million, while net profit fell to Rs 1,702 million from Rs 9,700 million (the prior year included a one-time Rs 6,075 million gain from sale of Syngene shares). Operating margins expanded YoY both standalone (23.84% vs 16.97%) and consolidated (22.78% vs 20.51%), with the Generics segment growing a strong 24% YoY. The Board granted in-principle approval to acquire the remaining ~2% stake in subsidiary Biocon Biologics Limited to make it a wholly owned subsidiary, with consideration to be paid via preferential allotment of Biocon shares, subject to shareholder and regulatory approvals.
The headline loss on standalone numbers and weak consolidated profit, driven mainly by one-time BBL integration and Labour Code costs, may weigh on sentiment in the near term. However, full ownership of BBL removes minority leakage and should enhance consolidated earnings going forward, while improved operating margins and strong Generics growth signal underlying business strength.